A congressional committee is demanding that the makers of controversial cholesterol drug Vytorin, Merck & Co. and Schering-Plough Corp., produce extensive data related to a clinical study indicating the drug might increase the risk of cancer.
Rep. John D. Dingell, chairman of the House Committee on Energy and Commerce, and Rep. Bart Stupak, chairman of its Oversight and Investigations Subcommittee, sent a letter Thursday to the chief executives of the drug company partners, giving them two weeks to supply detailed information about the study.
More.
No comments:
Post a Comment